Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Not Confirmed
Not Confirmed
13-16 July, 2025
Not Confirmed
Not Confirmed
14-16 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Not Confirmed
13-16 July, 2025
Industry Trade Show
Not Confirmed
14-16 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
17 Feb 2023
// CLINICAL TRIALS ARENA
https://www.clinicaltrialsarena.com/news/frontera-dosing-trial-gene-therapy/
02 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/02/2600496/0/en/Frontera-Therapeutics-Doses-First-Patient-in-a-Clinical-Trial-of-FT-003-Gene-Therapy-for-the-Treatment-of-Wet-AMD.html
06 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/01/06/2584482/0/en/Frontera-Therapeutics-Doses-First-Patient-in-Phase-1-Clinical-Trial-for-Gene-Therapy-FT-001-for-the-Treatment-of-Leber-Congenital-Amaurosis-2.html
Details:
FT-001 is administered by injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene. FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to RPE65 gene mutation.
Lead Product(s): FT-001
Therapeutic Area: Rare Diseases and Disorders Brand Name: FT-001
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2023
Lead Product(s) : FT-001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-001 is administered by injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene. FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to RPE65 gene mutation...
Product Name : FT-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 01, 2023
Details:
FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function. It treat patients with X-linked retinitis pigmentosa caused by RPGR gene mutation.
Lead Product(s): FT-002
Therapeutic Area: Genetic Disease Brand Name: FT-002
Study Phase: UndisclosedProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2023
Lead Product(s) : FT-002
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function. It treat patients with X-linked retinitis pigmentosa caused by RPGR gene muta...
Product Name : FT-002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 17, 2023
Details:
FT-003 is a gene therapy product for the treatment of neovascular age-related macular degeneration. It has the potential to provide durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients.
Lead Product(s): FT-003
Therapeutic Area: Ophthalmology Brand Name: FT-003
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2023
Lead Product(s) : FT-003
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT-003 is a gene therapy product for the treatment of neovascular age-related macular degeneration. It has the potential to provide durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients.
Product Name : FT-003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 02, 2023
Details:
Frontera’s FT-001 is an AAV gene therapy product administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.
Lead Product(s): FT-001
Therapeutic Area: Ophthalmology Brand Name: FT-001
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2022
Lead Product(s) : FT-001
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001
Details : Frontera’s FT-001 is an AAV gene therapy product administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.
Product Name : FT-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 21, 2022
ABOUT THIS PAGE